Literature DB >> 31984471

AUC- vs. Trough-Guided Monitoring of Vancomycin in Infants.

Abdullah Alsultan1,2, Manal Abouelkheir3, Ahmad Albassam4, Emad Alharbi3, Ahmed Assiri3, Saeed Alqahtani5,6.   

Abstract

OBJECTIVE: Improving vancomycin therapy with therapeutic drug monitoring is recommended. Over the past few years, a few studies have demonstrated that trough concentrations may not be the optimal parameter for monitoring vancomycin concentration and Area under the curve (AUC) should be used instead. In this study authors evaluate two methods to estimate the AUC. The first method is based on linear regression using only a trough concentration. The second method uses a simplified two-sample equation-based strategy to estimate the AUC.
METHODS: Data from 70 infant patients were collected retrospectively from their medical records at King Saud University Medical City. The prediction accuracy for vancomycin therapy monitoring was optimized by comparing the two methods for the AUC calculation, the simple linear regression and simplified two-sample equation-based strategy.
RESULTS: The target AUC > 400 μg × h/ml was achieved in 10%, 71%, and 100% of patients with trough concentration ranges of 5-10, 10-15, and > 15 μg/ml, respectively. There was a strong correlation between the predicted and observed AUC calculated using the simplified two-sample equation-based strategy (R2 = 0.91, bias = -3.9%, precision =12%).
CONCLUSIONS: The target AUC > 400 μg × h/ml can be achieved at trough concentrations <15 μg/ml in most patients. Targeting trough concentrations >15 can lead to overdoing and increase risk of nephrotoxicity. The authors recommend estimating the AUC using the simplified two-sample equation strategy for more precise dosing of vancomycin. Using AUC-guided dosing instead of the trough-guided approach can prevent over dosing and reduce the risk of nephrotoxicity.

Entities:  

Keywords:  Dosing; Infants; Pharmacokinetics; Vancomycin

Mesh:

Substances:

Year:  2020        PMID: 31984471     DOI: 10.1007/s12098-019-03162-5

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  33 in total

Review 1.  Vancomycin: a review of population pharmacokinetic analyses.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.

Authors:  Anthony M Casapao; Thomas P Lodise; Susan L Davis; Kimberly C Claeys; Ravina Kullar; Donald P Levine; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

3.  Vancomycin prescription in neonates and young infants: toward a simplified dosage.

Authors:  C Oudin; R Vialet; A Boulamery; C Martin; N Simon
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2011-03-06       Impact factor: 5.747

4.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children.

Authors:  Susan McKamy; Elvin Hernandez; Maximillian Jahng; Tiffany Moriwaki; Audra Deveikis; Jennifer Le
Journal:  J Pediatr       Date:  2011-03       Impact factor: 4.406

Review 6.  Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity.

Authors:  Manjunath P Pai; Keith A Rodvold
Journal:  Diagn Microbiol Infect Dis       Date:  2013-10-22       Impact factor: 2.803

Review 7.  Innovative approaches to optimizing the delivery of vancomycin in individual patients.

Authors:  Manjunath P Pai; Michael Neely; Keith A Rodvold; Thomas P Lodise
Journal:  Adv Drug Deliv Rev       Date:  2014-06-05       Impact factor: 15.470

8.  Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.

Authors:  Thomas P Lodise; Nimish Patel; Ben M Lomaestro; Keith A Rodvold; George L Drusano
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

9.  An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant Staphylococcus aureus.

Authors:  Chris Stockmann; Jared Olson; Jahidur Rashid; Lisa Lubsch; David C Young; Adam L Hersh; Adam Frymoyer; Krow Ampofo; Xiaoxi Liu; Yuhuan Wang; Catherine M T Sherwin; Jeffery T Zobell
Journal:  J Clin Pharmacol       Date:  2018-10-29       Impact factor: 3.126

10.  Incidence and predisposing factors of vancomycin-induced nephrotoxicity in children.

Authors:  Ahmed R Ragab; Maha K Al-Mazroua; Mona A Al-Harony
Journal:  Infect Dis Ther       Date:  2013-03-26
View more
  4 in total

1.  Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Staphylococcus aureus Infection?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2020-06-01

2.  Prediction of Area Under the Curve of Vancomycin in Infants: A Comparison of Two Methods.

Authors:  Nithya J Gogtay; Sandeep B Bavdekar
Journal:  Indian J Pediatr       Date:  2020-03-25       Impact factor: 1.967

3.  Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit.

Authors:  Bo Zhou; Wenyi Xiong; Ke Bai; Hongxing Dang; Jing Li; Feng Xu; Yue-Qiang Fu; Chengjun Liu
Journal:  Front Pediatr       Date:  2022-06-30       Impact factor: 3.569

4.  Heaping the Pelion of Vancomycin on the Ossa of Methicillin-resistant Staphylococcus aureus: Back to Basics in Clinical Care and Guidelines.

Authors:  William F Wright; Sarah C J Jorgensen; Brad Spellberg
Journal:  Clin Infect Dis       Date:  2021-05-18       Impact factor: 20.999

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.